(WGS) GeneDx Holdings - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 1.939m USD | Total Return: -21.1% in 12m

Genetic Testing, Sequencing, Diagnostics, Data Analysis
Total Rating 30
Safety 33
Buy Signal -0.59
Diagnostics & Research
Industry Rotation: +13.4
Market Cap: 1.94B
Avg Turnover: 47.6M USD
ATR: 7.44%
Peers RS (IBD): 8.7
Risk 5d forecast
Volatility75.3%
Rel. Tail Risk-13.0%
Reward TTM
Sharpe Ratio0.18
Alpha-51.19
Character TTM
Beta1.523
Beta Downside2.051
Drawdowns 3y
Max DD88.40%
CAGR/Max DD1.00
EPS (Earnings per Share) EPS (Earnings per Share) of WGS over the last years for every Quarter: "2021-03": -1.06, "2021-06": -0.21, "2021-09": -0.43, "2021-12": -0.17, "2022-03": -0.31, "2022-06": -0.25, "2022-09": -0.2, "2022-12": -0.25, "2023-03": -2.44, "2023-06": -1.64, "2023-09": -0.82, "2023-12": -0.69, "2024-03": -0.33, "2024-06": -0.1, "2024-09": 0.04, "2024-12": 0.6353, "2025-03": 0.2732, "2025-06": 0.5, "2025-09": 0.49, "2025-12": 0.14, "2026-03": 0,
EPS CAGR: 2.89%
EPS Trend: 62.3%
Last SUE: 0.17
Qual. Beats: 0
Revenue Revenue of WGS over the last years for every Quarter: 2021-03: 64.201, 2021-06: 47.015, 2021-09: 43.178, 2021-12: 57.801, 2022-03: 53.941, 2022-06: 36.169, 2022-09: 83.234, 2022-12: 61.35, 2023-03: 43.139, 2023-06: 48.706, 2023-09: 53.303, 2023-12: 57.418, 2024-03: 62.422, 2024-06: 70.514, 2024-09: 76.874, 2024-12: 95.64, 2025-03: 87.115, 2025-06: 102.692, 2025-09: 116.743, 2025-12: 120.989, 2026-03: null,
Rev. CAGR: 24.04%
Rev. Trend: 81.1%
Last SUE: 0.11
Qual. Beats: 0

Warnings

High Debt/EBITDA (7.1) with thin interest coverage (-7.3)

Interest Coverage Ratio -7.3 is critical

Altman Z'' -11.77 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: WGS GeneDx Holdings

GeneDx Holdings Corp. (WGS) is a genomics company specializing in genetic testing services.

Their primary focus is pediatric and rare disease diagnostics, utilizing whole exome and genome sequencing. This business model involves analyzing an individuals entire genetic code to identify disease-causing mutations.

GeneDx also develops an AI-based platform for advanced analysis and reporting of next-generation sequencing data. This technology is applied to rare disease, hereditary risk, and cancer testing, reflecting a growing trend in the healthcare sector towards precision medicine and data-driven diagnostics.

The company, founded in 2000, is headquartered in Stamford, Connecticut. Investors may find it beneficial to continue their research on ValueRay for comprehensive financial analysis.

Headlines to Watch Out For
  • Whole exome and genome sequencing drives diagnostic revenue
  • AI platform development expands testing capabilities
  • Pediatric and rare disease focus limits market size
  • Regulatory changes impact genetic testing approval
  • Reimbursement policies influence service profitability
Piotroski VR‑10 (Strict) 6.0
Net Income: -21.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA 10.61 > 1.0
NWC/Revenue: 37.28% < 20% (prev 46.87%; Δ -9.59% < -1%)
CFO/TA 0.06 > 3% & CFO 33.3m > Net Income -21.0m
Net Debt (46.9m) to EBITDA (6.63m): 7.09 < 3
Current Ratio: 2.46 > 1.5 & < 3
Outstanding Shares: last quarter (26.9m) vs 12m ago -0.38% < -2%
Gross Margin: 68.49% > 18% (prev 0.64%; Δ 6.79k% > 0.5%)
Asset Turnover: 86.41% > 50% (prev 72.83%; Δ 13.58% > 0%)
Interest Coverage Ratio: -7.32 > 6 (EBITDA TTM 6.63m / Interest Expense TTM 2.54m)
Altman Z'' -11.77
A: 0.28 (Total Current Assets 268.3m - Total Current Liabilities 108.9m) / Total Assets 570.2m
B: -2.41 (Retained Earnings -1.37b / Total Assets 570.2m)
C: -0.04 (EBIT TTM -18.6m / Avg Total Assets 494.8m)
D: -5.24 (Book Value of Equity -1.37b / Total Liabilities 262.0m)
Altman-Z'' Score: -11.77 = D
Beneish M -2.53
DSRI: 1.41 (Receivables 74.4m/37.6m, Revenue 427.5m/305.4m)
GMI: 0.93 (GM 68.49% / 63.64%)
AQI: 1.05 (AQ_t 0.41 / AQ_t-1 0.39)
SGI: 1.40 (Revenue 427.5m / 305.4m)
TATA: -0.10 (NI -21.0m - CFO 33.3m) / TA 570.2m)
Beneish M-Score: -2.53 (Cap -4..+1) = A
What is the price of WGS shares? As of April 08, 2026, the stock is trading at USD 66.89 with a total of 831,307 shares traded.
Over the past week, the price has changed by +4.16%, over one month by -29.22%, over three months by -51.01% and over the past year by -21.09%.
Is WGS a buy, sell or hold? GeneDx Holdings has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy WGS.
  • StrongBuy: 5
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the WGS price?
Analysts Target Price 148.9 122.6%
GeneDx Holdings (WGS) - Fundamental Data Overview as of 04 April 2026
P/E Forward = 44.843
P/S = 4.5351
P/B = 6.2278
Revenue TTM = 427.5m USD
EBIT TTM = -18.6m USD
EBITDA TTM = 6.63m USD
Long Term Debt = 48.2m USD (from longTermDebt, last quarter)
Short Term Debt = 8.95m USD (from shortTermDebt, last quarter)
Debt = 151.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 46.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.92b USD (1.94b + Debt 151.9m - CCE 171.3m)
Interest Coverage Ratio = -7.32 (Ebit TTM -18.6m / Interest Expense TTM 2.54m)
EV/FCF = 134.6x (Enterprise Value 1.92b / FCF TTM 14.3m)
FCF Yield = 0.74% (FCF TTM 14.3m / Enterprise Value 1.92b)
FCF Margin = 3.34% (FCF TTM 14.3m / Revenue TTM 427.5m)
Net Margin = -4.92% (Net Income TTM -21.0m / Revenue TTM 427.5m)
Gross Margin = 68.49% ((Revenue TTM 427.5m - Cost of Revenue TTM 134.7m) / Revenue TTM)
Gross Margin QoQ = 65.23% (prev 72.40%)
Tobins Q-Ratio = 3.37 (Enterprise Value 1.92b / Total Assets 570.2m)
Interest Expense / Debt = 0.34% (Interest Expense 520k / Debt 151.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -14.7m (EBIT -18.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.46 (Total Current Assets 268.3m / Total Current Liabilities 108.9m)
Debt / Equity = 0.49 (Debt 151.9m / totalStockholderEquity, last quarter 308.2m)
Debt / EBITDA = 7.09 (Net Debt 46.9m / EBITDA 6.63m)
Debt / FCF = 3.29 (Net Debt 46.9m / FCF TTM 14.3m)
Total Stockholder Equity = 283.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.25% (Net Income -21.0m / Total Assets 570.2m)
RoE = -7.41% (Net Income TTM -21.0m / Total Stockholder Equity 283.7m)
RoCE = -5.60% (EBIT -18.6m / Capital Employed (Equity 283.7m + L.T.Debt 48.2m))
 RoIC = -4.38% (negative operating profit) (NOPAT -14.7m / Invested Capital 335.7m)
 WACC = 10.54% (E(1.94b)/V(2.09b) * Re(11.34%) + D(151.9m)/V(2.09b) * Rd(0.34%) * (1-Tc(0.21)))
Discount Rate = 11.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.74%
[DCF] Terminal Value 60.11% ; FCFF base≈14.3m ; Y1≈9.36m ; Y5≈4.28m
[DCF] Fair Price = 0.41 (EV 59.0m - Net Debt 46.9m = Equity 12.1m / Shares 29.3m; r=10.54% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 62.27 | EPS CAGR: 2.89% | SUE: 0.17 | # QB: 0
Revenue Correlation: 81.13 | Revenue CAGR: 24.04% | SUE: 0.11 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.12 | Chg7d=+0.000 | Chg30d=-0.007 | Revisions Net=+2 | Analysts=7
EPS current Year (2026-12-31): EPS=0.91 | Chg7d=+0.073 | Chg30d=+0.075 | Revisions Net=+4 | Growth EPS=-34.9% | Growth Revenue=+28.6%
EPS next Year (2027-12-31): EPS=2.06 | Chg7d=+0.001 | Chg30d=+0.056 | Revisions Net=+3 | Growth EPS=+125.6% | Growth Revenue=+26.1%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle